NPS Report issue

Contributed to NME For profit Phase 3
Founded: Bedminster NJ United States (1986)
Status: Acquired by Shire (2015) → now Takeda (2018)

Organization Overview

First Clinical Trial
2004
NCT00081458
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2004

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (1)

teduglutide (gattex kit) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Short Bowel Syndrome (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1